-
公开(公告)号：KR102226569B1
公开(公告)日：2021-03-10
申请号：KR1020180138888A
申请日：2018-11-13
Applicant: 부경대학교 산학협력단 , 전북대학교산학협력단
IPC: A61K8/9789 , A23L3/3472 , A23L3/3544 , A61K8/49 , A61K8/60 , A61Q19/02
CPC classification number: A61K8/9789 , A23L3/3472 , A23L3/3544 , A61K8/498 , A61K8/602 , A61Q19/02 , A23V2002/00 , A23V2200/02 , A61K2800/782
Abstract: 본 발명은 엉겅퀴 추출물, 이의 분획물, 엉겅퀴 유래의 루테올린 또는 루테올린 5-
O -글루코사이드를 포함하는 피부 미백용 화장료 조성물 또는 식품의 갈변 방지용 조성물에 관한 것으로서, 상기 조성물은 티로시나제에 대한 억제 활성을 가짐으로써 피부 미백 뿐만 아니라 식품의 갈변 방지 효과가 있어 화장품 분야 및 식품 분야에서 유용하게 사용할 수 있다.-
2.发明专利
公开(公告)号：KR20210025871A
公开(公告)日：2021-03-10
申请号：KR1020190105801A
申请日：2019-08-28
Applicant: 부경대학교 산학협력단 , 전북대학교산학협력단
IPC: A61K31/122 , A23L33/10 , A61P25/00 , A61P25/28
CPC classification number: A61K31/122 , A23L33/10 , A61P25/00 , A61P25/28 , A23V2002/00 , A23V2200/322 , A23V2250/30
Abstract: 본 발명은 7-하이드록시이모딘을 유효성분으로 포함하는 신경질환의 예방 또는 치료용 조성물에 관한 것으로서, 상기 7-하이드록시이모딘은 도파민 D
3 수용체에 의한 신호전달을 촉진하고, 바소프레신 V
1A 수용체 및 세로토닌 1A 수용체에 의한 신호전달을 저해함으로써 퇴행성 신경질환, 조현병 또는 자폐증 등의 신경질환의 예방 또는 치료에 유용하게 사용될 수 있다.-
3.发明申请
公开(公告)号：WO2014098512A1
公开(公告)日：2014-06-26
申请号：PCT/KR2013/011924
申请日：2013-12-20
Applicant: 부경대학교 산학협력단
Abstract: 본 발명은 푸코스테롤의 퇴행성 신경질환 치료의 신규 용도에 관한 것으로, 자세하게는 푸코스테롤을 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약제학적 조성물 및 건강기능식품에 관한 것이다. 본 발명의 푸코스테롤은 α-세크레타아제(α-secretase)인 ADAM10의 발현을 효과적으로 증대시킬 수 있으므로, 이를 유효성분으로 포함하는 본 발명의 조성물은 아밀로이드 베타(Aβ) 펩티드 생성 억제 효과가 우수하여 알츠하이머와 같은 퇴행성 신경질환의 예방 또는 치료(개선)를 위한 약제학적 의약품, 기능성 식품 등에 유용하게 사용될 수 있다. 특히 본 발명의 푸코스테롤은 천연물로부터 유래된 물질로서, 세포독성 없이 안정성을 가지므로, 이를 유효성분으로 포함하는 본 발명의 조성물은 인체에 부작용 없이 장기적 사용에도 안전한 이점을 가진다.
Abstract translation: 本发明涉及一种用于治疗神经退行性疾病的岩藻甾醇的新用途，更具体地，涉及包含用于预防或治疗神经变性疾病的作为活性成分的岩藻甾醇的药物组合物和功能保健食品。 本发明的岩藻甾醇可以有效地增加作为α-分泌酶的ADAM10的表达。 因此，含有作为活性成分的岩藻甾醇的本发明的组合物具有抑制淀粉样蛋白β（生产）肽生产的优异效果，因此可有效地用于药物，功能性食品等中，用于预防 或治疗（减轻）神经变性疾病如阿尔茨海默病。 特别地，本发明的岩藻甾醇衍生自天然物质，没有细胞毒性，并具有稳定性。 因此，作为活性成分的含有岩藻糖醇的本发明的组合物具有长期使用安全的优点，不会对人体造成副作用。
-
4.发明公开매생이 추출물 또는 이로부터 분리된 화합물을 유효성분으로 포함하는 당뇨성 합병증 예방 또는 치료용 약제학적 조성물 无效用于预防或治疗包含卡泊芬粉或其分离的化合物的糖尿病综合症的药物组合物
公开(公告)号：KR1020130140448A
公开(公告)日：2013-12-24
申请号：KR1020120063862
申请日：2012-06-14
Applicant: 부경대학교 산학협력단 , 대구가톨릭대학교산학협력단
Abstract: The present invention relates to novel uses of capsosiphon fulvescens extract or compounds isolated therefrom for preventing or treating diabetic complications and, more specifically, to a pharmaceutical composition and a health supplement for preventing or treating diabetic complications which include capsosiphon fulvescens extract, soluble extract of non-polar solvent, or compounds isolated therefrom (capsofulvesin A, capsofulvesin B, chalinasterol) as active ingredients. The capsosiphon fulvescens extracts or compounds isolated therefrom (capsofulvesin A, capsofulvesin B, chalinasterol) have excellent suppression activities on aldose reductase and excellent suppression activities on final glycation products. Therefore, the capsosiphon fulvescens extracts or compounds isolated therefrom can be utilized as medicines such as pharmaceutical compositions and health supplements for preventing or treating diabetic complications so that the value of the capsosiphon fulvescens extracts or compounds isolated therefrom can be extremely high when applying in food and medical industries. Specially, the capsosiphon fulvescens extracts or compounds isolated therefrom in the present invention are substances derived from natural substances and have stability without cytotoxicity so that the compositions of the present invention which includes the same as active ingredients can be safely used for long time.
Abstract translation: 本发明涉及一种用于预防或治疗糖尿病并发症的胆红素提取物或其分离的化合物的新用途，更具体地，涉及用于预防或治疗糖尿病并发症的药物组合物和健康补充剂，其包括辣椒皂苷提取物，非可溶性提取物， - 极性溶剂，或从其分离的化合物（海藻多柔比星A，棉铃藓素B，沙拉宁醇）作为活性成分。 辣椒油提取物或从其中分离的化合物（海藻多糖A，血浆壳多糖B，沙利度醇）对醛糖还原酶具有优异的抑制活性，对最终糖基化产物具有优异的抑制活性。 因此，辣椒油提取物或其分离的化合物可用作药物，例如用于预防或治疗糖尿病并发症的药物组合物和健康补充剂，从而当应用于食物中时，辣椒素提取物或从其分离的化合物的值可能非常高 医疗行业。 特别地，在本发明中，辣椒油提取物或从其分离的化合物是天然物质衍生的物质，具有稳定性而没有细胞毒性，因此本发明的包含与活性成分相同的组合物可以长时间安全使用。
-
公开(公告)号：KR1020140025914A
公开(公告)日：2014-03-05
申请号：KR1020120092486
申请日：2012-08-23
Applicant: 부경대학교 산학협력단
IPC: A61K31/336 , A61K36/03 , A61P3/10
Abstract: The present invention relates to novel uses of prevention or treatment of diabetic complications of fucoxanthin, specifically, to a pharmaceutical composition for preventing or treating (improving) diabetic complications which includes fucoxanthin derived from sea brown algae such as Eiseniabicyclis, Undariapinnatifida or Hijikiafusiformis as active ingredients, to health supplement, and to insulin sensitive enhancer. The fucoxanthin of the present invention has enhanced inhibition activities of aldose reductase and advanced glycation end-products, and improves insulin resistance by increasing insulin signal transduction through PTP1B suppression activities. Therefore, the fucoxanthin of the present invention can be utilized as a drug such as pharmaceutical composition and health supplement which can prevent or treat the diabetic complications so that the fucoxanthin has greatly high value if applied to food and medicine industries. Especially, the fucoxanthin of the present invention has safety without cytotoxicity as a material derived from natural material so that the composition including the same as the active ingredient can be safe for long term use.
Abstract translation: 本发明涉及预防或治疗岩藻黄素的糖尿病并发症的新用途，具体地，涉及用于预防或治疗（改善）糖尿病并发症的药物组合物，其包括衍生自海藻褐藻类的藻黄素，例如茜草属，，ida ida或Hijikia fusiformis作为活性成分 ，健康补充剂和胰岛素敏感增强剂。 本发明的岩藻黄质具有增强的醛糖还原酶和晚期糖基化终产物的抑制活性，并且通过PTP1B抑制活性增加胰岛素信号转导来改善胰岛素抵抗。 因此，本发明的岩藻黄质可以用作可以预防或治疗糖尿病并发症的药物，例如药物组合物和健康补充剂，如果应用于食品和药物工业，则岩藻黄质具有非常高的价值。 特别地，本发明的岩藻黄质具有安全性而没有细胞毒性作为源自天然材料的材料，因此含有活性成分的组合物对于长期使用来说是安全的。
-
Patent Agency Ranking
公开(公告)号：KR1020210043189A
公开(公告)日：2021-04-21
申请号：KR1020190126052
申请日：2019-10-11
Applicant: 부경대학교 산학협력단 , 전북대학교산학협력단
IPC: A61K31/122 , A61P25/00 , A61P25/28 , A23L33/10
Abstract: 본발명은이모딘을유효성분으로포함하는신경질환의예방또는치료용조성물에관한것으로서, 상기이모딘은도파민 D3 수용체에의한신호전달을촉진하고, 바소프레신 V1A 수용체에의한신호전달을저해함으로써퇴행성신경질환, 조현병또는자폐증등의신경질환의예방또는치료에유용하게사용될수 있다.
-
公开(公告)号：KR1020140081339A
公开(公告)日：2014-07-01
申请号：KR1020120150980
申请日：2012-12-21
Applicant: 부경대학교 산학협력단
Abstract: The present invention relates to a novel use of fucosterol to treat degenerative nervous diseases and, specifically, to a pharmaceutical composition and a health functional food including fucosterol as an active ingredient for preventing or treating degenerative nervous diseases. The fucosterol of the present invention can effectively increase the expression of ADAM10 which is α-secretase. Accordingly, the composition of the present invention which includes the same as an active ingredient has an excellent effect in controlling the formation of amyloid beta (Aβ) peptides so that the composition can be usefully used for a pharmaceutical product and a functional food for preventing or treating (alleviating) degenerative nervous diseases. The fucosterol of the present invention is especially a material derived from a natural material so as to have stability without cytotoxicity. Thus, the composition of the present invention which includes the same as an active ingredient is advantageously safe without causing side effects in the human body even after used for a long time.
Abstract translation: 本发明涉及岩藻甾醇治疗退行性神经疾病的新用途，具体涉及药物组合物和包含岩藻糖醇作为预防或治疗退行性神经疾病的有效成分的保健功能性食品。 本发明的岩藻甾醇能够有效地增加作为α-分泌酶的ADAM10的表达。 因此，包括与活性成分相同的本发明的组合物在控制淀粉样蛋白β（Aβ）肽的形成方面具有优异的效果，使得该组合物可有效地用于药物产品和用于预防或 治疗（减轻）退行性神经疾病。 本发明的岩藻甾醇特别是衍生自天然材料的材料，以具有无细胞毒性的稳定性。 因此，即使长时间使用，本发明的包含与活性成分相同的组合物也是安全的，而不会在人体内引起副作用。
-
8.发明公开항산화활성을 갖는 연수 추출물 및 그로부터 분리된플라보노이드 화합물을 함유한 조성물 失效具有包含从NELUMBO NUCIFERA STAMEN分离的提取物和黄酮类化合物的抗氧化活性的组合物
公开(公告)号：KR1020040072146A
公开(公告)日：2004-08-18
申请号：KR1020030008105
申请日：2003-02-10
Applicant: 부경대학교 산학협력단
CPC classification number: A61K36/62 , A23L2/38 , A23L33/105 , A23V2002/00 , A23V2200/308 , A61K9/14 , A61K31/352 , A61K2236/33
Abstract: PURPOSE: A composition having antioxidation activity comprising the extract and flavonoid compounds isolated from Nelumbo nucifera stamen is provided, thereby inhibiting formation of reactive oxygen species(ROS) and inhibiting activity of DPPH radical and lipid peroxide ion, so that it can be useful for prevention and treatment of diseases caused by oxidative stresses. CONSTITUTION: The composition having antioxidation activity comprises a crude extract of Nelumbo nucifera stamen, wherein the crude extract of Nelumbo nucifera stamen is prepared by using a polar solvent selected from water, methanol, butanol or a mixture thereof or a nonpolar solvent selected from ethylacetate, n-hexane, methylene chloride, and chloroform. The composition having antioxidation activity comprises flavonoid compounds isolated from Nelumbo nucifera stamen represented by formula (I), and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen, hydroxy, C1-C4 alkyl or alkoxy, gluco, rhamnogluco(Rha(1>6)-Glu), galacto, glucurono, or lower alkyl glucurono; and R2 and R3 are independently hydrogen, hydroxy, C1-C4 alkyl or alkoxy.
Abstract translation: 目的：提供具有抗氧化活性的组合物，其含有从Nelumbo nucifera雄蕊中分离的提取物和类黄酮化合物，从而抑制活性氧（ROS）的形成和抑制DPPH自由基和脂质过氧化物离子的活性，从而可用于预防 并治疗由氧化应激引起的疾病。 构成：具有抗氧化活性的组合物包括Nelumbo nucifera雄蕊的粗提物，其中Nelumbo nucifera雄蕊的粗提物通过使用选自水，甲醇，丁醇或其混合物的极性溶剂或选自乙酸乙酯， 正己烷，二氯甲烷和氯仿。 具有抗氧化活性的组合物包括从由式（I）表示的Nelumbo nucifera雄蕊分离的类黄酮化合物及其药学上可接受的盐，其中R1是氢，羟基，C1-C4烷基或烷氧基，葡萄糖，鼠李糖醇（Rha（1） -Glu），半乳糖，葡糖醛酸或低级烷基葡糖苷酸; R2和R3独立地是氢，羟基，C1-C4烷基或烷氧基。
-
公开(公告)号：KR102250681B1
公开(公告)日：2021-05-11
申请号：KR1020190126054
申请日：2019-10-11
Applicant: 부경대학교 산학협력단 , 전북대학교산학협력단
IPC: A61K31/122 , A61K36/48 , A61P25/24 , A23L33/10
Abstract: 본발명은결명자에서분리된화합물인옵투신, 알로에-에모딘또는퀘스틴을유효성분으로포함하는우울증의예방또는치료용조성물에관한것으로서, 상기옵투신, 알로에-에모딘또는퀘스틴은 MAO-A (monoamine oxidase A)에대한경쟁적저해활성을가지고있어우울증의예방또는치료에유용하게사용될수 있다.
-
公开(公告)号：KR102250675B1
公开(公告)日：2021-05-11
申请号：KR1020190105801
申请日：2019-08-28
Applicant: 부경대학교 산학협력단 , 전북대학교산학협력단
IPC: A61K31/122 , A61P25/00 , A61P25/28 , A23L33/10
Abstract: 본발명은 7-하이드록시에모딘을유효성분으로포함하는신경질환의예방또는치료용조성물에관한것으로서, 상기 7-하이드록시에모딘은도파민 D3 수용체에의한신호전달을촉진하고, 바소프레신 V1A 수용체및 세로토닌 1A 수용체에의한신호전달을저해함으로써퇴행성신경질환, 조현병또는자폐증등의신경질환의예방또는치료에유용하게사용될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.025 seconds)
